The HUPO 2020 World Congress is pleased to welcome the confirmed presenters for the upcoming Congress taking place October 18 - 22, 2020 in Stockholm, Sweden. The fantastic line-up includes academics, industry professionals and powerhouses from around the world.
Li-Ming Gan, MD Ph.D. is a chief physician in non-invasive cardiology and holds a professorship in translational cardiovascular research and drug discovery at Sahlgrenska Academy at Sahlgrenska University Hospital in Gothenburg, Sweden. Li-Ming joined AstraZeneca for 18 years ago and been responsible for the atherosclerosis and heart failure pipeline between 2007-2011. Between 2011-2013, he worked as a Translational Science Director to help bridging the early projects into the human setting. Since 2013, Li-Ming has been appointed as a Senior Director Physician in early clinical research unit and being responsible for phase I and II clinical programs within the cardiovascular area.
To date, Li-Ming and his team has brought a number of projects from target ideas through preclinical translational research into clinical testing in areas of atherosclerosis, thrombosis, and heart failure. Li-Ming has also through his work established broad scientific network worldwide within the cardiometabolic area. Li-Ming has also pioneered the clinical development work using novel modalities, such as modified messenger RNA. Since April 2019, Li-Ming was appointed as VP and global head of early clinical development for the cardiovascular, renal and metabolism area at BioPharmaceuticals R&D, AstraZeneca.
Nathalie Y.R. Agar, Ph.D. is the Daniel E. Ponton Distinguished Chair in Neurosurgery at Brigham and Women’s Hospital and Associate Professor of Neurosurgery and of Radiology at Harvard Medical School. Dr. Agar’s multidisciplinary training includes a B.Sc. in Biochemistry, Ph.D. in Chemistry, a postdoctoral fellowship in Neurology and Neurosurgery from McGill University, and further postdoctoral training in Neurosurgery at BWH/HMS. From this unique background, she has developed distinct skills to address unmet analytical needs in the clinical environment. She has also developed a network of specialists to satisfy the many different aspects of translational research activities.
Her research aims to develop and implement comprehensive molecular diagnoses through improved biochemical classifications. This will ultimately enable surgeons and oncologists to tailor treatment from the time of surgery, and allow precision cancer care using molecular imaging with mass spectrometry approaches. She is developing and validating a direct in vivo mass spectrometry analysis of surgical tissue to assist in real time tissue characterization. Her laboratory also focuses on the mass spectrometry imaging of drugs and metabolism from pre-clinical animal models and clinical trials’ specimens to study targeted therapeutics for brain tumors.
David Weitz received his PhD in physics from Harvard University and then joined Exxon Research and Engineering Company, where he worked for nearly 18 years. He then became a professor of physics at the University of Pennsylvania and moved to Harvard at the end of the last millennium as professor of physics and applied physics. He leads a group studying soft matter science with a focus on microfluidics, biophysics, materials science and flow in porous media. Several startup companies have come from his lab to commercialize research concepts.
Amy Herr is a Professor of Bioengineering at the University of California, Berkeley and a Chan Zuckerberg Biohub Investigator. Prior to joining UC Berkeley, she was a staff member at Sandia National Labs, earned Ph.D. and M.S. degrees in Mechanical Engineering from Stanford University, and completed her B.S. in Engineering and Applied Science with honors from Caltech. Her research has been recognized by the NIH New Innovator Award, NSF CAREER Award, Alfred P. Sloan Fellowship (Chemistry), and DARPA Young Faculty Award, & Visionary Award from the City of Berkeley and named to the Analytical Scientist’s top 100 most influential people in analytical science.
Professor Herr has chaired the Gordon Research Conference (GRC) on the Physics & Chemistry of Microfluidics and will chair microTAS 2020. She is an elected Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and the US National Academy of Inventors, an entrepreneur, and was recently appointed to the National Advisory Council of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at NIH. Her research program lies at the intersection of engineering design, analytical chemistry, and targeted proteomics – with a recent focus on cytometry spanning fundamental biological to clinical questions.
Malin Parmar is a professor in cellular neuroscience at Lund University in Sweden and a New York Stem Cell Foundation – Robertson investigator. Together with her lab she has shown in a series of high-profile publications how human fibroblasts can be converted into neurons, how glial cells can be reprogrammed into neurons in vivo, and how functional dopamine neurons can be generated from human embryonic stem cells.
She is the recipient of an ERC starting grant and an ERC Consolidator grant. Her research has a strong translational focus, she leads the European effort STEM-PD, designed to bring stem cell-derived dopamine neurons to clinical trials, and she collaborates within European and International networks as well as Industry partners to develop new, cell based therapies for Brain Repair with focus on Parkinson’s Disease.
Keep up to date with Official Congress News